Literature DB >> 12690116

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

Lan Zhu1, Constantin Tamvakopoulos, Dan Xie, Jasminka Dragovic, Xiaolan Shen, Judith E Fenyk-Melody, Keith Schmidt, Ansuman Bagchi, Patrick R Griffin, Nancy A Thornberry, Ranabir Sinha Roy.   

Abstract

Dipeptidyl peptidase IV (DP-IV) is a cell surface serine dipeptidase that is involved in the regulation of the incretin hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). There is accumulating evidence that other members of the glucagon family of peptides are also endogenous substrates for this enzyme. To identify candidate substrates for DP-IV, a mass spectrometry-based protease assay was developed that measures cleavage efficiencies (kcat/Km) of polypeptides in a mixture, using only a few picomoles of each substrate and physiological amounts of enzyme in a single kinetic experiment. Oxyntomodulin and the growth hormone-(1-43) fragment were identified as new candidate in vivo substrates. Pituitary adenylate cyclase-activating polypeptide-(1-38) (PACAP38), a critical mediator of lipid and carbohydrate metabolism, was also determined to be efficiently processed by DP-IV in vitro. The catabolism of exogenously administered PACAP38 in wild type and DP-IV-deficient C57Bl/6 mice was monitored by tandem mass spectrometry. Animals lacking DP-IV exhibited a significantly slower clearance of the circulating peptide with virtually complete suppression of the inactive DP-IV metabolite, PACAP-(3-38). These in vivo results suggest that DP-IV plays a major role in the degradation of circulating PACAP38.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690116     DOI: 10.1074/jbc.M212355200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

2.  What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

Authors:  B Ahrén
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

3.  Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships.

Authors:  Charles G Starr; Jerome L Maderdrut; Jing He; David H Coy; William C Wimley
Journal:  Peptides       Date:  2018-04-11       Impact factor: 3.750

Review 4.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 5.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

Review 6.  The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight.

Authors:  Audrey Melvin; Carel W le Roux; Neil G Docherty
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

7.  Global identification of peptidase specificity by multiplex substrate profiling.

Authors:  Anthony J O'Donoghue; A Alegra Eroy-Reveles; Giselle M Knudsen; Jessica Ingram; Min Zhou; Jacob B Statnekov; Alexander L Greninger; Daniel R Hostetter; Gang Qu; David A Maltby; Marc O Anderson; Joseph L Derisi; James H McKerrow; Alma L Burlingame; Charles S Craik
Journal:  Nat Methods       Date:  2012-09-30       Impact factor: 28.547

8.  Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Authors:  David A D'Alessio; Amanda M Denney; Linda M Hermiller; Ronald L Prigeon; Julie M Martin; William G Tharp; Monica Liqueros Saylan; Yanling He; Beth E Dunning; James E Foley; Richard E Pratley
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

Review 9.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

10.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.